Iovance Biotherapeutics' Lifileucel BLA Priority Review Extended: FDA Extends PDUFA Date To February 24, 2024 Amid Resource Constraints
Portfolio Pulse from Benzinga Newsdesk
The FDA has extended the PDUFA date for Iovance Biotherapeutics' Lifileucel BLA Priority Review to February 24, 2024 due to resource constraints.
September 15, 2023 | 5:40 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA's extension of the PDUFA date for Iovance Biotherapeutics' Lifileucel BLA Priority Review could delay the company's plans.
The FDA's extension of the PDUFA date for Iovance Biotherapeutics' Lifileucel BLA Priority Review could potentially delay the company's plans. This could have a negative impact on the company's stock in the short term as investors may see this as a setback.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100